Kitchener, Ontario, July 8, 2019 -- James E. Wagner Cultivation Corporation (“JWC” or the “Corporation”) (TSX VENTURE: JWCA; OTCQX: JWCAF), is pleased to announce that on July 5, 2019, it received approval of a licence amendment from Health Canada, allowing for the sale of formulated cannabis oil from the Corporation’s pilot facility, JWC 1, located at 855 Trillium Drive in Kitchener, ON. JWC intends to commence the sale of formulated cannabis oil to its medical patients on July 9, 2019.

“Formulated oil is an important market sector, both for its medical importance to a wide variety of patients, but also for its impact on the business practices of a Licensed Producer. With the addition of our oil sales licence, JWC is fully licensed and able to participate in all aspects of the cannabis industry,” said the Corporation’s President and Chief Executive Officer, Nathan Woodworth, in response to the Corporation’s receipt of Health Canada’s approval to sell formulated cannabis oil.

JWC is thrilled to expand its product offerings to include formulated cannabis oil, which will be available in multiple sizes, including 25 ml and 50 ml bottles of JWC’s THC and Balanced THC:CBD oils. The Corporation’s high CBD oil is available in a 25 ml bottle, containing a total of 2500mg of CBD.

JWC is eager and excited to provide patients with affordable and accessible medical cannabis oils, in addition to the variety of dried cannabis products already available, which are grown using its proprietary GrowthSTORM™ Dual Droplet™ System.

Sales of cannabis oil will commence on July 9, 2019 at 9:00 am, EST, at which time current or newly registered JWC medical enrollees become eligible to purchase the Corporation’s select oil varieties. To enquire about becoming a JWC medical patient, please visit www.jwc.ca/register.

JWC – Clean, consistent, aeroponic.

About James E. Wagner Cultivation Corporation

JWC’s wholly-owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis. JWC uses an advanced and proprietary Dual Droplet™ aeroponic platform named GrowthSTORM™. JWC was founded as a family company and is based on family values. JWC began as a collective of patients and growers under the Marihuana Medical Access Regulations (the precursor to ACMPR). Since its inception, JWC has remained focused on providing the best possible patient experience. JWC’s operations are based in Kitchener, Ontario. Learn more at www.jwc.ca.

For additional information about JWC, please refer to JWC’s profile on SEDAR (www.sedar.com) or the Corporation’s website: www.jwc.ca

Notice regarding forward-looking statements:

This press release contains statements including forward-looking information for purposes of applicable securities laws (“forward-looking statements”) about JWC and its business and operations which include, among other things, statements regarding the assortment of products available from the Corporation, including formulated cannabis oil, the sale of these products to medical patients and the future sale to recreational customers throughout Canada. The forward-looking statements can be identified by the use of such words as “will”, “expected”, “approximately”, “may”, “could”, “would” or similar words and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those implied in the forward-looking statements. For example, risks include risks regarding the cannabis industry, economic factors, the equity markets generally, building permit related risks and risks associated with growth and competition as well as the risks identified in the Corporation’s Annual Information Form dated April 3, 2019, available under the Corporation’s profile at www.sedar.com. Although JWC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are based on current assumptions which management believes to be reasonable. The Corporation disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information about this release, please contact:

Nathan Woodworth, President & CEO of JWC
Email: nathan@jwc.ca
Phone: (519) 594-0144 x421

OR

George Aizpurua, Vice President of First Canadian Capital Corp.
Email: gaizpurua@firstcanadiancapital.com
Phone: (416) 742-5600